Comparison Between Myoinositol and Metformin on Biochemical Profile in Women with Polycystic Ovarian Syndrome

  • Zaib Un Nisa Medical Frequency and Healthcare Clinic, DG Khan
  • Faiza Murtaza Ahmed Medical Complex, Rawalpindi
  • Sidra Kiran Medicsi Hospital, Rawalpindi
  • Sehrish Sabir Benazir Bhutto Hospital (BBH), Rawalpindi
  • Sidra Anam Tehsil Headquarter Hospital (THQ) Hazro, Dist. Attock
  • Irem Khurshid Akhtar Saeed Medical College, Rawalpindi
Keywords: Biomarkers, Inositol, Metformin, Polycystic ovarian syndrome

Abstract

Background: The most common endocrine disorder in women during their reproductive years is polycystic ovary syndrome. Metformin is one of the effective oral insulin sensitizing agent it is also considered first line agent in the treatment of this syndrome. Myoinositol is a new emerging agent in the treatment of polycystic, evidences are showing myoinositol is the good addition for the treatment of polycystic syndrome.

Objectives: To compare the outcome of myoinositol and metformin on biochemical profile in women with polycystic ovarian disease.

Methods: This comparative randomized controlled trial was carried out at the Gynecology and Obstetrics Department of Benazir Bhutto Hospital Rawalpindi, from October 2022 to April 2023. The study involved 100 female patients aged 18 to 35 diagnosed with polycystic ovarian syndrome. The participants randomly were assigned to two groups: Group-I received myoinositol (1 gram twice daily) for 24 weeks, and Group-II received metformin (500mg thrice daily) for the same duration. Hormonal parameters, including FSH, LH, LH/FSH ratio, and fasting blood glucose (measured after 8 hours of overnight fasting), were assessed at baseline and after 24 weeks.

Results: The patients mean age was 28.12±4.84 years. The metformin-treated group exhibited mean baseline values of 7.65±2.79, 5.19±1.79, 1.54±0.68, and 90.82±10.72 for LH, FSH, LH/FSH ratio, and fasting blood sugar, respectively. After 24 weeks of treatment, these values decreased to 6.16±2.57, 4.34±1.65, 1.50±0.68, and 85.96±5.72 (p ≤ 0.05). In the myoinositol-treated group, the mean baseline values were 6.37±3.90, 4.66±1.37, 1.51±1.29, and 88.52±11.13 for LH, FSH, LH/FSH ratio, and fasting blood sugar, respectively. After 24 weeks of treatment, these values decreased to 4.54±2.56, 3.71±1.39, 1.37±1.05, and 88.10±4.43 (p ≤ 0.05).

Conclusion: This study concluded that myoinositol demonstrates superior efficacy compared to metformin in enhancing the biochemical profile of individuals with polycystic ovarian syndrome.

Author Biographies

Zaib Un Nisa, Medical Frequency and Healthcare Clinic, DG Khan

FCPS (Obstetrics and Gynaecology),

Consultant Gynecologist

Faiza Murtaza, Ahmed Medical Complex, Rawalpindi

FCPS (Obstetrics and Gynaecology),

Consultant Gynecologist

Sidra Kiran, Medicsi Hospital, Rawalpindi

FCPS (Obstetrics and Gynecology),

Consultant Gynecologist

Sehrish Sabir, Benazir Bhutto Hospital (BBH), Rawalpindi

FCPS, MRCOG (Obstetrics and Gynecology),

Senior Registrar

Sidra Anam, Tehsil Headquarter Hospital (THQ) Hazro, Dist. Attock

FCPS (Obstetrics and Gynaecology),

Consultant Gynecologist

Irem Khurshid, Akhtar Saeed Medical College, Rawalpindi

MBBS, MCPS (Obstetrics and Gynaecology),

Senior Registrar

Published
2024-04-02
Section
Original Articles